Search Results - "Li, G. Ying"

Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel by Small, David S., Farid, Nagy A., Payne, Christopher D., Weerakkody, Govinda J., Li, Ying G., Brandt, John T., Salazar, Daniel E., Winters, Kenneth J.

“…Prasugrel and clopidogrel, thienopyridine prodrugs, are each metabolized to an active metabolite that inhibits the platelet P2Y12 ADP receptor. In this…”
Get full text

The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration by Jakubowski, Joseph A, Payne, Christopher D, Li, Ying G, Brandt, John T, Small, David S, Farid, Nagy A, Salazar, Daniel E, Winters, Kenneth J

“…Variability in response to antiplatelet agents has prompted the development of point-of-care (POC) technology. In this study, we compared the VerifyNow P2Y12…”
Get more information

A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry by Jakubowski, Joseph A, Payne, Christopher D, Li, Ying G, Farid, Nagy A, Brandt, John T, Small, David S, Salazar, Daniel E, Winters, Kenneth J

“…Platelet inhibition as measured by vasodilator-stimulated phosphoprotein (VASP) and light transmission aggregometry (LTA) have shown concordance following…”
Get more information

Relationship Between Exposure to Prasugrel Active Metabolite and Clinical Outcomes in the TRITON-TIMI 38 Substudy by Riesmeyer, Jeffrey S., Salazar, Daniel E., Weerakkody, Govinda J., Ni, Lan, Wrishko, Rebecca E., Ernest II, C. Steven, Luo, Junxiang, Li, Ying G., Small, David S., Rohatagi, Shashank, Macias, William L.

“…In TRITON-TIMI 38, levels of the prasugrel active metabolite (pras-AM) were measured in a population pharmacokinetic substudy that characterized the intrinsic…”
Get full text

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11) by Frias, Juan P, Bonora, Enzo, Nevarez Ruiz, Luis, Li, Ying G, Yu, Zhuoxin, Milicevic, Zvonko, Malik, Raleigh, Bethel, M Angelyn, Cox, David A

“…To compare efficacy and safety of dulaglutide at doses of 3.0 and 4.5 mg versus 1.5 mg in patients with type 2 diabetes inadequately controlled with metformin…”
Get full text

Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy chinese and white volunteers: An open-label trial by Small, David S., PhD, Payne, Christopher D., MS, Kothare, Prajakti, PhD, Yuen, Eunice, BPharm, Natanegara, Fanni, PhD, Teng Loh, Mei, PhD, Jakubowski, Joseph A., PhD, Richard Lachno, D., DPhil, Li, Ying G., MS, Winters, Kenneth J., MD, Farid, Nagy A., PhD, Ni, Lan, PhD, Salazar, Daniel E., PhD, Tomlin, Molly, MS, Kelly, Ronan, MD, DPhil

“…Abstract Background: Prasugrel is an oral antiplatelet agent approved for the reduction of atherothrombotic cardiovascular events in patients presenting with…”
Get full text

Integrated Analysis of Pharmacokinetic Data Across Multiple Clinical Pharmacology Studies of Prasugrel, a New Thienopyridine Antiplatelet Agent by Small, David S., Li, Ying G., Ernest II, C. Steven, April, John H., Farid, Nagy A., Payne, Christopher D., Winters, Kenneth J., Rohatagi, Shashank, Ni, Lan

“…An integrated analysis of pharmacokinetic (PK) parameter estimates for prasugrel, from 16 phase I clinical pharmacology studies, consolidated exposure…”
Get full text

Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Subjects by Farid, Nagy A., Small, David S., Payne, Christopher D., Jakubowski, Joseph A., Brandt, John T., Li, Ying G., Ernest II, C. Steven, Salazar, Daniel E., Konkoy, Christopher S., Winters, Kenneth J.

“…Study Objective. To investigate the potential effect of atorvastatin 80 mg/day on the pharmacokinetics and pharmacodynamics of the thienopyridines prasugrel…”
Get full text

Eliminating Unnecessary Opioid Exposure After Common Children's Surgeries by Harbaugh, Calista M, Vargas, Gracia, Streur, Courtney Shepard, Li, G Ying, Thatcher, Aaron L, Waljee, Jennifer F, Gadepalli, Samir K

Get more information

Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo‐controlled trial in patients with type 2 diabetes using metformin by Frias, Juan P., Wynne, Alan G., Matyjaszek‐Matuszek, Beata, Bartaskova, Dagmar, Cox, David A., Woodward, Brad, Li, Ying G., Tham, Lai S., Milicevic, Zvonko

“…Aims Dulaglutide, a once weekly GLP‐1 receptor agonist, is approved at two doses (1.5 and 0.75 mg) for treatment of type 2 diabetes (T2D). Two higher doses of…”
Get full text

Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects by Payne, Christopher D., Li, Ying G., Brandt, John T., Jakubowski, Joseph A., Small, David S., Farid, Nagy A., Salazar, Daniel E., Winters, Kenneth J.

“…Prasugrel, a novel P2Y12 antagonist, achieves faster onset and greater inhibition of platelet aggregation than clopidogrel 300 and 600 mg loading doses (LD)…”
Get full text

A retrospective comparison of intrathecal morphine and epidural hydromorphone for analgesia following posterior spinal fusion in adolescents with idiopathic scoliosis by Hong, Rebecca A., Gibbons, Kathleen M., Li, G. Ying, Holman, Ashlee, Voepel‐Lewis, Terri, Bosenberg, Adrian

“…Summary Background Posterior spinal fusion to correct idiopathic scoliosis is associated with severe postoperative pain. Intrathecal morphine is commonly used…”
Get full text

TWO TREATMENT APPROACHES FOR HUMAN REGULAR U-500 INSULIN IN PATIENTS WITH TYPE 2 DIABETES NOT ACHIEVING ADEQUATE GLYCEMIC CONTROL ON HIGH-DOSE U-100 INSULIN THERAPY WITH OR WITHOUT ORAL AGENTS: A RANDOMIZED, TITRATION-TO-TARGET CLINICAL TRIAL by Hood, Robert C, Arakaki, Richard F, Wysham, Carol, Li, Ying G, Settles, Julie A, Jackson, Jeffrey A

“…To compare the efficacy and safety of 2 dosing regimens for human regular U-500 insulin (U-500R, 500 units/mL) replacing high-dose U-100 insulins with or…”
Get more information

The relationship between parental factors, child symptom profile, and persistent postoperative pain interference and analgesic use in children by Siemer, Lauren C., Foxen‐Craft, Emily, Malviya, Shobha, Ramirez, Mark, Li, G. Ying, James, Chrystina, Voepel‐Lewis, Terri, Walker, Suellen

“…Objectives Both parental and child factors have been previously associated with persistent or recurrent postoperative pain in children. Yet, little is known…”
Get full text

OPTIMIZED HUMAN REGULAR U-500 INSULIN TREATMENT IMPROVES β-CELL FUNCTION IN SEVERELY INSULIN-RESISTANT PATIENTS WITH LONG-STANDING TYPE 2 DIABETES AND HIGH INSULIN REQUIREMENTS by Mari, Andrea, Rosenstock, Julio, Ma, Xiaosu, Li, Ying G, Jackson, Jeffrey A

“…To assess β-cell function and insulin sensitivity following improvement in glycemic control in severely insulin-resistant patients with poorly controlled type…”
Get more information

Paper 63: Remodeling of Adolescent Displaced Clavicle Fractures: A FACTS Study by Bae, Donald, Boutelle, Kelly, Busch, Michael, Carroll, Alyssa, Edmonds, Eric, Ellis, Henry, Hergott, Katelyn, Kocher, Mininder, Li, G. Ying, Nepple, Jeffrey, Pandya, Nirav, Perkins, Crystal, Polinsky, Samuel, Sabatini, Coleen, Spence, David, Willimon, Samuel, Wilson, Philip, Heyworth, Benton, Pennock, Andrew

“…Objectives: The phenomenon of bony remodeling of healed displaced clavicle midshaft fractures in adolescents remains poorly understood. The purpose of the…”
Get full text

Population Pharmacokinetic Analyses to Evaluate the Influence of Intrinsic and Extrinsic Factors on Exposure of Prasugrel Active Metabolite in TRITON-TIMI 38 by Wrishko, Rebecca E., Ernest II, C. Steven, Small, David S., Li, Ying G., Weerakkody, Govinda J., Riesmeyer, Jeffrey R., Macias, William L., Rohatagi, Shashank, Salazar, Daniel E., Antman, Elliott M., Wiviott, Stephen D., Braunwald, Eugene, Ni, Lan

“…Serial pharmacokinetic (PK) sampling in 1159 patients from TRITON‐TIMI 38 was undertaken. A multilinear regression model was used to quantitatively predict…”
Get full text

pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects by Small, David S, Kothare, Prajakti, Yuen, Eunice, Lachno, D. Richard, Li, Ying G, Winters, Kenneth J, Farid, Nagy A, Ni, Lan, Jakubowski, Joseph A, Salazar, Daniel E, Thieu, Vivian T, Payne, Christopher D

“…Purpose Prasugrel is a novel thienopyridine prodrug metabolised to an active metabolite that binds irreversibly to the platelet P2Y₁₂ receptor and inhibits…”
Get full text

Operative Versus Non-Operative Treatment of Severely Shortened or Comminuted Clavicle Fractures in Older Adolescent Athletes: Results from A Prospective, Multicenter, Level 2 Cohort Study by Wilson, Philip, Bae, Donald, Busch, Michael, Edmonds, Eric, Ellis, Henry, Hergott, Katelyn, Kocher, Mininder, Li, G. Ying, Liotta, Elizabeth, Nepple, Jeffrey, Pandya, Nirav, Pennock, Andrew, Perkins, Crystal, Sabatini, Coleen, Williams, David, Willimon, S. Clifton, Heyworth, Benton, Spence, David

“…Objectives: Operative management of clavicle fractures is increasingly advocated for athletes and young adults. Surgical indications and optimal treatment for…”
Get full text

A Comparison of the VerifyNow P2Y12 Point-of-Care Device and Light Transmission Aggregometry to Monitor Platelet Function with Prasugrel and Clopidogrel: An Integrated Analysis by Jakubowski, Joseph A, Li, Ying G, Small, David S, Payne, Christopher D, Tomlin, Molly E, Luo, Junxiang, Winters, Kenneth J

“…We compared platelet function results obtained with the VerifyNow P2Y12 (VN-P2Y12) point-of-care device and the light transmission aggregometry (5 and 20 μM…”
Get full text